First Hawaiian Bank Biomarin Pharmaceutical Inc Transaction History

First Hawaiian Bank

$2.84 Billion
Q1 2025

A detailed history of First Hawaiian Bank transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, First Hawaiian Bank holds 14,700 shares of BMRN stock, worth $869,799. This represents 0.04% of its overall portfolio holdings.

Number of Shares

14,700

Previous 14,700 -0.0%

Holding current value

$869,799

Previous $966,000 7.56%

% of portfolio

0.04%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 08, 2025	BUY	$61.93 - $70.49 $12,386 - $14,097	200 Added 1.38%	14,700 $966,000
Q3 2024 Oct 04, 2024	SELL	$69.02 - $93.84 $69,020 - $93,840	-1,000 Reduced 6.45%	14,500 $1.02 Million
Q2 2024 Jul 02, 2024	SELL	$74.43 - $92.22 $29,772 - $36,888	-400 Reduced 2.52%	15,500 $1.28 Million
Q1 2024 Apr 05, 2024	SELL	$83.81 - $99.0 $2,681 - $3,168	-32 Reduced 0.2%	15,900 $1.39 Million
Q4 2023 Jan 08, 2024	BUY	$76.22 - $98.51 $32,927 - $42,556	432 Added 2.79%	15,932 $1.54 Million
Q4 2021 Jan 12, 2022	BUY	$71.72 - $91.47 $1.11 Million - $1.42 Million	15,500 New	15,500 $1.37 Million
Q3 2019 Oct 03, 2019	SELL	$67.4 - $85.11 $424,620 - $536,193	-6,300 Closed	0 $0
Q2 2019 Jul 15, 2019	SELL	$80.35 - $93.9 $211,722 - $247,426	-2,635 Reduced 29.49%	6,300 $540,000
Q1 2019 Apr 02, 2019	BUY	$84.2 - $98.62 $16,840 - $19,724	200 Added 2.29%	8,935 $794,000
Q4 2018 Jan 11, 2019	SELL	$80.14 - $106.07 $8,014 - $10,607	-100 Reduced 1.13%	8,735 $744,000
Q3 2018 Oct 16, 2018	BUY	$93.92 - $105.72 $829,783 - $934,036	8,835 New	8,835 $857,000

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

184M

Call Options Held

Put Options Held

1.67M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Hawaiian Bank with notifications on news.

Account

First Hawaiian Bank Biomarin Pharmaceutical Inc Transaction History